New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
11:57 EDTTHRX, P, GDI, CIEN, BYD, SSYSOptions with decreasing implied volatility: THRX P GDI CIEN BYD SSYS
News For THRX;P;GDI;CIEN;BYD;SSYS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 23, 2014
15:30 EDTPNotable companies reporting after market close
Subscribe for More Information
12:51 EDTPPandora technical comments before results
Subscribe for More Information
07:52 EDTSSYSStratasys positioned for good Q3, solid Q4, says Jefferies
Jefferies says its reseller survey indicates Stratasys (SSYS) had a good Q3 and is set for a solid Q4, in contrast to peer 3D Systems (DDD). The firm notes it survey suggests Stratasys is discounting more than 3D, which it attributes to the company reinvesting currency benefits. Jefferies says Stratasys remains its top pick. It has a Buy rating on the stock with a $155 price target.
October 22, 2014
14:43 EDTTHRXTheravance drops after partner announces restructuring, posts abstracts
Shares of Theravance, (THRX) a biopharmaceutical company that has economic ties to GlaxoSmithKline (GSK), are lower in afternoon trading after Glaxo reported restructuring plans. Additionally, Theravance disclosed last night that GSK is scheduled to present data from Phase 3 studies at an upcoming medical conference. CHEST 2014 in Austin, Texas, to be held from October 25-30. WHAT'S NEW: Earlier today, GlaxoSmithKline announced it intends to refocus its global pharmaceuticals business and cost base following the divestment of its oncology products and the changed dynamics now faced in the U.S. respiratory market. Theravance has strategic alliances with GlaxoSmithKline in respiratory products. Also, Theravance disclosed last night that Glaxo is scheduled to present data from Phase 3 studies at CHEST 2014, which is being held from October 25-30. Umeclidinium/Vilanterol, a once-daily combination treatment comprising two bronchodilators in Theravance's ELLIPTA inhaler, and Fluticasone Furoate/Vilanterol, a once-daily combination of a LABA and inhaled corticosteroid, have been developed under a collaboration pact between Glaxo and Theravance. Abstracts of the planned oral presentations can be found in the CHEST Journal, Theravance noted in its filing. PRICE ACTION: In afternoon trading, shares of Theravance fell 10.25% to $16.73.
11:18 EDTPPandora launches marketing platform AMP for artists
Subscribe for More Information
11:14 EDTTHRXHigh option volume stocks
Subscribe for More Information
10:09 EDTSSYSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
October 21, 2014
16:17 EDTSSYSStratasys initiated with a Perform at Oppenheimer
15:22 EDTPPandora volatility elevated into Q3 and outlook
Pandora October weekly call option implied volatility is at 135, November is at 70, December is at 58, January is at 57; compared to its 26-week average of 55 according to Track Data, suggesting large price movement into the expected release of Q3 results on October 23.
October 20, 2014
07:24 EDTPPandora expected to meet/beat high-end of Q3 guidance, says Wedbush
Subscribe for More Information
October 17, 2014
10:31 EDTPPandora calls active on renewed speculation of an activist investor
Subscribe for More Information
10:20 EDTPPandora spikes higher, levels to watch
Shares are up 3% to $22.70 on a sharp spike in the last ten minutes. At current price resistance is at $23.23. Support is at $22.45, the opening price of the day.
10:16 EDTPRumor: Pandora moves up on renewed speculation of an activist investor
Subscribe for More Information
05:25 EDTTHRXTheravance announces positive Anoro Ellipta study data published
Subscribe for More Information
October 16, 2014
09:30 EDTSSYSStratasys upgraded to Overweight from Equal Weight at Stephens
October 15, 2014
14:10 EDTBYDPennsylvania reports September gaming revenue down 2.2% to $239.5M
Subscribe for More Information
14:06 EDTBYDAtlantic City reports September gaming win down 12.8% to $209.4M
Subscribe for More Information
10:50 EDTPPandora November volatility elevated into Q3 and outlook
Subscribe for More Information
07:32 EDTSSYSUBM Canon to hold a conference
PLASTEC Midwest Conference is being held in Chicago on October 15-16.
October 13, 2014
07:22 EDTPSony/ATV could ditch licensing firms due to streaming dollars, NY Post reports
Sony/ATV Music Publishing (SNE) is considering no longer dealing with performance rights groups BMI and ASCP, and instead negotiating directly with online music services like Pandora (P), YouTube (GOOG) and Spotify due to outdated rules and low royalties, the New York Post reports. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use